Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Smidt Simon (Brasília, Brazil), C. Melo-Silva (Brasília, Brazil), P. Veloso (Brasília, Brazil), L. Coelho (Brasília, Brazil), J. Longo (Brasília, Brazil), L. Vianna (Brasília, Brazil), V. Amado (Brasília, Brazil), A. Bocca (Brasília, Brazil). Peptide ToAP3 from T. obscurus interferes with idiopathic pulmonary fibrosis progression in murine model.. 1372

Member's Comments

No comment yet.

Related content which might interest you: A novel chronic murine model of idiopathic pulmonary fibrosis Source: International Congress 2018 – Pulmonary fibrosis: from models to patients Year: 2018 Analysis of the lung microbiota in healthy dogs and in canine idiopathic pulmonary fibrosis, a possible spontaneous model for human IPF. Source: International Congress 2018 – Pulmonary fibrosis: from models to patients Year: 2018 Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Down-regulation of inhibitory of growth family member 4(ING4) in idiopathic pulmonary fibrosis (IPF). Correlation with disease progression Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009 Reactivation of developmental pathways in idiopathic pulmonary fibrosis: FGF9 and FGF18 modulate the phenotype of control and fibrotic human lung fibroblasts in vitro Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Etablishing rhesus model of pulmonary fibrosis (PF) for the new drug evaluation Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 In vitro modelling of epithelia-fibroblast interactions in idiopathic pulmonary fibrosis Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019 The potential role of antimicrobial peptides from wasp as regulators of the fibrotic process in idiopathic pulmonary fibrosis. Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis? Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Expression of hyaluronidase by interstitial myofibroblasts and epithelial cells is associated with fibrosis extension, clinical forms and pulmonary function stage in patients with systemic sclerosis Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 The pathogenesis of pulmonary fibrosis: a moving target Source: Eur Respir J 2013; 41: 1207-1218 Year: 2013 The role of extracellular vesicles in phenotypic alteration of lung cells in pulmonary fibrosis Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Endotrophin is related to disease progression in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 RhoA signalling influences cyclin D1 expression and associated fibroblast turnover: implications for idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006 The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016